Tracy Cannon-Smith, MD
Urogynecology and Reconstructive Pelvic Surgery · Arlington, TXNPI 1942297569
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Caldera Medical, Inc at 32.6% of the total. Reporting peaked in 2019 at $11,268 and has fallen 87.6% since, to $1,394 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $106.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$9K
- Medtronic$9K
- Axonics, Inc.$6K
- AbbVie$482
- Astellas Pharma US Inc$482
- Boston Scientific$439
- plus $3K from 32 others
Across 2 payments — averaging $1048.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$12,10042%
- Speaking & faculty fees$2,2658%
- Grants$1140%
- Travel & lodging$4,03914%
- Food & beverage$9,75734%
- Education$250%
- Gifts$5802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 10 | $9,418 |
| Medtronic(2 entities) | 76 | $8,886 |
| Axonics, Inc. | 29 | $6,085 |
| AbbVie(2 entities) | 23 | $482 |
| Astellas Pharma US Inc | 28 | $482 |
| Boston Scientific | 9 | $439 |
| Bayer | 23 | $383 |
| Valencia Technologies Corporation | 9 | $328 |
| Johnson & Johnson | 4 | $233 |
| Urogen Pharma, Inc. | 5 | $224 |
| Kerecis Limited | 2 | $224 |
| Coloplast | 2 | $178 |
| Agiliti Surgical, Inc. | 2 | $161 |
| Contura, Inc. | 2 | $146 |
| Ferring Pharmaceuticals Inc. | 3 | $145 |
| Dendreon Pharmaceuticals LLC | 6 | $132 |
| Bluewind Medical | 2 | $128 |
| Femselect Inc. | 2 | $108 |
| Sun Pharmaceutical Industries Inc. | 2 | $103 |
| Olympus America Inc. | 4 | $83 |
| Tolmar Pharmaceuticals, Inc. | 6 | $82 |
| Merck | 3 | $59 |
| Innovation Technologies Inc | 1 | $48 |
| Travere Therapeutics, Inc. | 2 | $43 |
| Myovant Sciences Inc. | 2 | $34 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| AstraZeneca | 2 | $26 |
| AMAG Pharmaceuticals, Inc. | 1 | $25 |
| Covidien LP | 1 | $24 |
| Neotract Inc. | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $18 |
| Sanofi | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Photocure Inc | 1 | $16 |
| Novartis | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
| Mission Pharmacal Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$9,200
- Vertessa$8,800
- Axonics r-SNM System$3,300
- INTERSTIM$3,078
- Axonics$2,168
- Bulkamid$1,928
- Kerecis Omega3 Marigen$801
- ALTAVIVA$603
- Kerecis Omega3 SurgiClose$200
- TITAN$163
- JELMYTO$119
- Erleada$117
- AKEEGA$117
- Lupron Depot$114
- eCoin Device Kit$102
How this compares
$28,879 in reported general payments places this provider in the 90th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 610 | $432,239 |
| GemtesaVibegron | 63 | $50,969 |
| Mirabegron ErMirabegron | 85 | $46,826 |
| Estradiol | 254 | $18,403 |
| Trospium Chloride ErTrospium Chloride | 56 | $9,855 |
| Methenamine Hippurate | 77 | $7,731 |
| Solifenacin Succinate | 100 | $4,965 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 77 | $3,358 |
| Trospium Chloride | 61 | $3,105 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 29 | $2,749 |
| CefuroximeCefuroxime Axetil | 167 | $1,861 |
| NitrofurantoinNitrofurantoin Macrocrystal | 35 | $1,680 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $1,440 |
| Ampicillin Trihydrate | 30 | $650 |
| Cephalexin | 38 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $482 | $432,239610 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Arlington
- Keith XavierArlington$282K
- Stephen KrausSan Antonio$372K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Teresa IrwinSan Marcos$20K
- Oluwarotimi NetteyHouston$19K
- Vaneesha Vallabh-PatelSan Antonio$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.